Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 100%

LABA/LAMA vs placebo

Adverse events (3‐week to 1‐year · Adults with COPD

Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in adverse events (3‐week to 1‐year compared with placebo (high certainty).

1 finding from 1 review

Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes only
OR 0.95 [0.86, 1.04]
17 studies · 8235 participants
High

LABA/LAMA vs placebo

Serious adverse events (3‐week to 1‐year · Adults with COPD

Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).

1 finding from 1 review

Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes only
OR 1.06 [0.88, 1.28]
22 studies · 10536 participants
High